1. Home
  2. HAIN vs RNTX Comparison

HAIN vs RNTX Comparison

Compare HAIN & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hain Celestial Group Inc. (The)

HAIN

Hain Celestial Group Inc. (The)

HOLD

Current Price

$0.63

Market Cap

70.2M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.96

Market Cap

80.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAIN
RNTX
Founded
1993
2001
Country
United States
United States
Employees
N/A
10
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
70.2M
80.7M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
HAIN
RNTX
Price
$0.63
$0.96
Analyst Decision
Hold
Buy
Analyst Count
9
2
Target Price
$2.23
$10.00
AVG Volume (30 Days)
720.1K
475.0K
Earning Date
05-11-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,457,769,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.89
52 Week High
$1.95
$2.18

Technical Indicators

Market Signals
Indicator
HAIN
RNTX
Relative Strength Index (RSI) 35.89 38.81
Support Level $0.58 N/A
Resistance Level $0.73 $1.33
Average True Range (ATR) 0.06 0.08
MACD -0.02 0.00
Stochastic Oscillator 2.19 24.28

Price Performance

Historical Comparison
HAIN
RNTX

About HAIN Hain Celestial Group Inc. (The)

The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby & kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas, among others. It operates under two reportable segments: North America and International. The majority of its revenue is derived from the North America segment, which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: